Thomas U Ahearn,Haoyu Zhang,Kyriaki Michailidou,Roger L Milne,Manjeet K Bolla,Joe Dennis,Alison M Dunning,Michael Lush,Qin Wang,Irene L Andrulis,Hoda Anton-Culver,Volker Arndt,Kristan J Aronson,Paul L Auer,Annelie Augustinsson,Adinda Baten,Heiko Becher,Sabine Behrens,Javier Benitez,Marina Bermisheva,Carl Blomqvist,Stig E Bojesen,Bernardo Bonanni,Anne-Lise Børresen-Dale,Hiltrud Brauch,Hermann Brenner,Angela Brooks-Wilson,Thomas Brüning,Barbara Burwinkel,Saundra S Buys,Federico Canzian,Jose E Castelao,Jenny Chang-Claude,Stephen J Chanock,Georgia Chenevix-Trench,Christine L Clarke,NBCS Collaborators,J Margriet Collée,Angela Cox,Simon S Cross,Kamila Czene,Mary B Daly,Peter Devilee,Thilo Dörk,Miriam Dwek,Diana M Eccles,D Gareth Evans,Peter A Fasching,Jonine Figueroa,Giuseppe Floris,Manuela Gago-Dominguez,Susan M Gapstur,José A García-Sáenz,Mia M Gaudet,Graham G Giles,Mark S Goldberg,Anna González-Neira,Grethe I Grenaker Alnæs,Mervi Grip,Pascal Guénel,Christopher A Haiman,Per Hall,Ute Hamann,Elaine F Harkness,Bernadette A M Heemskerk-Gerritsen,Bernd Holleczek,Antoinette Hollestelle,Maartje J Hooning,Robert N Hoover,John L Hopper,Anthony Howell,ABCTB Investigators,kConFab/AOCS Investigators,Milena Jakimovska,Anna Jakubowska,Esther M John,Michael E Jones,Audrey Jung,Rudolf Kaaks,Saila Kauppila,Renske Keeman,Elza Khusnutdinova,Cari M Kitahara,Yon-Dschun Ko,Stella Koutros,Vessela N Kristensen,Ute Krüger,Katerina Kubelka-Sabit,Allison W Kurian,Kyriacos Kyriacou,Diether Lambrechts,Derrick G Lee,Annika Lindblom,Martha Linet,Jolanta Lissowska,Ana Llaneza,Wing-Yee Lo,Robert J MacInnis,Arto Mannermaa,Mehdi Manoochehri,Sara Margolin,Maria Elena Martinez,Catriona McLean,Alfons Meindl,Usha Menon,Heli Nevanlinna,William G Newman,Jesse Nodora,Kenneth Offit,Håkan Olsson,Nick Orr,Tjoung-Won Park-Simon,Alpa V Patel,Julian Peto,Guillermo Pita,Dijana Plaseska-Karanfilska,Ross Prentice,Kevin Punie,Katri Pylkäs,Paolo Radice,Gad Rennert,Atocha Romero,Thomas Rüdiger,Emmanouil Saloustros,Sarah Sampson,Dale P Sandler,Elinor J Sawyer,Rita K Schmutzler,Minouk J Schoemaker,Ben Schöttker,Mark E Sherman,Xiao-Ou Shu,Snezhana Smichkoska,Melissa C Southey,John J Spinelli,Anthony J Swerdlow,Rulla M Tamimi,William J Tapper,Jack A Taylor,Lauren R Teras,Mary Beth Terry,Diana Torres,Melissa A Troester,Celine M Vachon,Carolien H M van Deurzen,Elke M van Veen,Philippe Wagner,Clarice R Weinberg,Camilla Wendt,Jelle Wesseling,Robert Winqvist,Alicja Wolk,Xiaohong R Yang,Wei Zheng,Fergus J Couch,Jacques Simard,Peter Kraft,Douglas F Easton,Paul D P Pharoah,Marjanka K Schmidt,Montserrat García-Closas,Nilanjan Chatterjee,Kristine K Sahlberg,Lars Ottestad,Rolf Kåresen,Ellen Schlichting,Marit Muri Holmen,Toril Sauer,Vilde Haakensen,Olav Engebråten,Bjørn Naume,Alexander Fosså,Cecile E Kiserud,Kristin V Reinertsen,Åslaug Helland,Margit Riis,Jürgen Geisler,Christine Clarke,Rosemary Balleine,Robert Baxter,Stephen Braye,Jane Carpenter,Jane Dahlstrom,John Forbes,CSoon Lee,Deborah Marsh,Adrienne Morey,Nirmala Pathmanathan,Rodney Scott,Peter Simpson,Allan Spigelman,Nicholas Wilcken,Desmond Yip,Nikolajs Zeps,Stephen Fox,Ian Campbell,David Bowtell,Amanda Spurdle,Penny Webb,Anna de Fazio,Margaret Tassell,Judy Kirk,Geoff Lindeman,Melanie Price,Melissa Southey,Roger Milne,Sid Deb

Abstract:Background: Genome-wide association studies (GWAS) have identified multiple common breast cancer susceptibility variants. Many of these variants have differential associations by estrogen receptor (ER) status, but how these variants relate with other tumor features and intrinsic molecular subtypes is unclear. Methods: Among 106,571 invasive breast cancer cases and 95,762 controls of European ancestry with data on 173 breast cancer variants identified in previous GWAS, we used novel two-stage polytomous logistic regression models to evaluate variants in relation to multiple tumor features (ER, progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and grade) adjusting for each other, and to intrinsic-like subtypes. Results: Eighty-five of 173 variants were associated with at least one tumor feature (false discovery rate < 5%), most commonly ER and grade, followed by PR and HER2. Models for intrinsic-like subtypes found nearly all of these variants (83 of 85) associated at p < 0.05 with risk for at least one luminal-like subtype, and approximately half (41 of 85) of the variants were associated with risk of at least one non-luminal subtype, including 32 variants associated with triple-negative (TN) disease. Ten variants were associated with risk of all subtypes in different magnitude. Five variants were associated with risk of luminal A-like and TN subtypes in opposite directions. Conclusion: This report demonstrates a high level of complexity in the etiology heterogeneity of breast cancer susceptibility variants and can inform investigations of subtype-specific risk prediction.

Reclassification of Two MLH1 Variants of Uncertain Significance Utilizing Clinical and Functional Data

Prevalence and Reclassification of BRCA1 and BRCA2 Variants in a Large, Unselected Chinese Han Breast Cancer Cohort

Application of a 5-Tiered Scheme for Standardized Classification of 2,360 Unique Mismatch Repair Gene Variants in the InSiGHT Locus-Specific Database.

Variant classification changes over time in the clinical molecular diagnostic laboratory setting

Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay

Functional analysis and clinical classification of 462 germline BRCA2 missense variants affecting the DNA binding domain

Identification of Lung Cancer Histology-Specific Variants Applying Bayesian Framework Variant Prioritization Approaches Within the TRICL and ILCCO Consortia.

When Two plus Four Does Not Equal Six: Combining Computational and Functional Evidence Towards Classification of BRCA1 Key Domain Missense Substitutions.

Reclassification of BRCA1 and BRCA2 variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort

Abstract 5615: Functional analysis of variants of uncertain significance in the MSH6 mismatch repair gene

Segregation, immunohistochemical, molecular and functional analyses classify a novel missense variant in fumarate hydratase (FH) as pathogenic

Evidence for classification of c.1852_1853AA>GC in MLH1 as a neutral variant for Lynch syndrome

Abstract PR09: Functional and clinical characterization of hypomorphic missense variants in the BRCA2 cancer predisposition gene

Supplementary Table from Classification of <i>brca2</i> Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay

Classification of genetic variants in genes associated with Lynch syndrome using a clinical history weighting algorithm

Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification

Abstract 7325: Integration of functional data to classify BRCA1/2 missense variants: An ENIGMA project

Biallelic germline nonsense variant of MLH3 underlies polyposis predisposition

Common variants in breast cancer risk loci predispose to distinct tumor subtypes

Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C

Detection of a major Lynch Syndrome-causing MLH1 founder variant in a large-scale genotyped cohort